Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vivus completes enrollment for Phase III Equip trial
The Equip study (OB-302) has enrolled over 1,250 morbidly obese patients with a body mass index (BMI) that equals or exceeds 35. The co-primary endpoints for these studies
The Equip study (OB-302) has enrolled over 1,250 morbidly obese patients with a body mass index (BMI) that equals or exceeds 35. The co-primary endpoints for these studies
Voclosporin is a next generation calcineurin inhibitor, which recently completed a Phase IIb North American trial for the prevention of kidney rejection following transplantation. Robert Foster, Isotechnika’s chairman
The lawsuit alleges that River’s Edge unlawfully promotes its benzoyl peroxide gel and wash products as generically equivalent to or otherwise substitutable for Graceway’s Benziq family of products.
The study showed that a specific Locked Nucleic Acid (LNA) antimiR that binds to the liver-specific microRNA-122 can readily enter the liver and antagonize the miRNA target molecule.
The immunotherapy reportedly helps allergy sufferers by building immunity to a wide variety of targeted allergens through the administration of low homeopathic concentrations of such allergens. Over time,
The open label clinical trial is composed of two parts: a Phase I dose escalation study designed to evaluate the safety, tolerability and pharmacokinetics of TRU-016; and a
The company previously said that the trial had been suspended pending an interim analysis, following which the company would make a decision regarding whether the trial ought to
Novelos has agreed to sell 100 shares of series D convertible preferred stock, having a stated value equal to $50,000 per share, a cumulative annual dividend of 9%
The goal of the Phase II clinical trial is to further determine safety of the Neurologix gene transfer therapy and to confirm the initial efficacy reported in the
The initial results are expected by the second week of May, 2008. These animal studies will be conducted by Krishna Menon, a world-renowned authority in preclinical and toxicological